Financial Survey: Phibro Animal Health (NASDAQ:PAHC) and Indivior (NASDAQ:INDV)

Phibro Animal Health (NASDAQ:PAHC) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Earnings and Valuation

This table compares Phibro Animal Health and Indivior”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52 billion	1.00	$99.72 million	$2.44	15.27
Indivior	$1.24 billion	3.42	$210.00 million	$2.79	12.88

Indivior has lower revenue, but higher earnings than Phibro Animal Health. Indivior is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Phibro Animal Health has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Phibro Animal Health and Indivior’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Indivior	26.65%	-283.11%	36.85%

Insider and Institutional Ownership

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 48.5% of Phibro Animal Health shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Phibro Animal Health and Indivior, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0	2	1	1	2.75
Indivior	0	2	5	0	2.71

Phibro Animal Health currently has a consensus price target of $47.67, indicating a potential upside of 27.96%. Indivior has a consensus price target of $45.17, indicating a potential upside of 25.65%. Given Phibro Animal Health’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Phibro Animal Health is more favorable than Indivior.

Summary

Phibro Animal Health beats Indivior on 8 of the 15 factors compared between the two stocks.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.